Presence of gustatory and olfactory dysfunction in the time of the COVID-19 pandemic.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
26 Jun 2021
Historique:
received: 14 02 2021
accepted: 03 06 2021
entrez: 27 6 2021
pubmed: 28 6 2021
medline: 1 7 2021
Statut: epublish

Résumé

The unexpected outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused more than 49 million cases and an estimated 2,000,000 associated deaths worldwide. In Germany, there are currently more than 2,000,000 laboratory-confirmed coronavirus disease 2019 (COVID-19) cases including 51,800 deaths. However, regional differences also became apparent and with the second wave of infections, the detailed characterization of COVID-19 patients is crucial to early diagnosis and disruption of chains of infections. Handing out detailed questionnaires to all individuals tested for COVID-19, we evaluated the clinical characteristics of negative and positive tested individuals. Expression of symptoms, symptom duration and association between predictor variables (i.e. age, gender) and a binary outcome (olfactory and gustatory dysfunction) were assessed. Overall, the most common symptoms among individuals who tested positive for SARS-CoV-2 were fatigue, headache, and cough. Olfactory and gustatory dysfunction were also reported by many SARS-CoV-2 negative individuals, more than 20% of SARS-CoV-2 negative tested individuals in our study reported olfactory and gustatory dysfunction. Independent of SARS-CoV-2 status, more females displayed symptoms of gustatory (29.8%, p = 0.0041) and olfactory dysfunction (22.9%, p = 0.0174) compared to men. Bringing early SARS-CoV-2 tests to the populations at risk must be a main focus for the upcoming months. The reliability of olfactory and gustatory dysfunction in COVID-19 negative tested individuals requires deeper investigation in the future.

Sections du résumé

BACKGROUND BACKGROUND
The unexpected outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused more than 49 million cases and an estimated 2,000,000 associated deaths worldwide. In Germany, there are currently more than 2,000,000 laboratory-confirmed coronavirus disease 2019 (COVID-19) cases including 51,800 deaths. However, regional differences also became apparent and with the second wave of infections, the detailed characterization of COVID-19 patients is crucial to early diagnosis and disruption of chains of infections.
METHODS METHODS
Handing out detailed questionnaires to all individuals tested for COVID-19, we evaluated the clinical characteristics of negative and positive tested individuals. Expression of symptoms, symptom duration and association between predictor variables (i.e. age, gender) and a binary outcome (olfactory and gustatory dysfunction) were assessed.
RESULTS RESULTS
Overall, the most common symptoms among individuals who tested positive for SARS-CoV-2 were fatigue, headache, and cough. Olfactory and gustatory dysfunction were also reported by many SARS-CoV-2 negative individuals, more than 20% of SARS-CoV-2 negative tested individuals in our study reported olfactory and gustatory dysfunction. Independent of SARS-CoV-2 status, more females displayed symptoms of gustatory (29.8%, p = 0.0041) and olfactory dysfunction (22.9%, p = 0.0174) compared to men.
CONCLUSIONS CONCLUSIONS
Bringing early SARS-CoV-2 tests to the populations at risk must be a main focus for the upcoming months. The reliability of olfactory and gustatory dysfunction in COVID-19 negative tested individuals requires deeper investigation in the future.

Identifiants

pubmed: 34174816
doi: 10.1186/s12879-021-06294-2
pii: 10.1186/s12879-021-06294-2
pmc: PMC8234756
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

612

Subventions

Organisme : NIEHS NIH HHS
ID : 27307C0012
Pays : United States

Références

Appetite. 2014 Dec;83:236-41
pubmed: 25192896
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2251-2261
pubmed: 32253535
Cell. 2020 Aug 20;182(4):812-827.e19
pubmed: 32697968
Lancet. 2011 Dec 17;378(9809):2112-22
pubmed: 21783242
Ear Nose Throat J. 2021 Apr;100(2_suppl):169S-173S
pubmed: 33236918
ACS Chem Neurosci. 2020 Apr 1;11(7):995-998
pubmed: 32167747
Int J Neurosci. 2008 Jan;118(1):137-47
pubmed: 18041611
Clin Infect Dis. 2020 Dec 31;71(11):3017-3018
pubmed: 32474587
World J Otorhinolaryngol Head Neck Surg. 2018 Mar 26;4(1):84-91
pubmed: 30035266
Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2389-2390
pubmed: 32328771
ORL J Otorhinolaryngol Relat Spec. 2009;71(5):268-72
pubmed: 19797935
BMJ. 2020 Jul 1;370:m2516
pubmed: 32611558
J Infect. 2020 Oct;81(4):614-620
pubmed: 32650110
Int Forum Allergy Rhinol. 2020 Jul;10(7):821-831
pubmed: 32329222
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
BMJ Open. 2018 Jan 31;8(1):e018788
pubmed: 29391364
Eur J Clin Nutr. 2015 Jul;69(7):781-5
pubmed: 26014268
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
World Allergy Organ J. 2020 May 16;13(5):100124
pubmed: 32426089
Drug Discov Today. 2015 Nov;20(11):1398-406
pubmed: 26160059
Cell Discov. 2020 Feb 24;6:11
pubmed: 32133153
Int Arch Allergy Immunol. 2020;181(2):128-135
pubmed: 31805564
Clin Infect Dis. 2020 Nov 19;71(16):2262-2264
pubmed: 32357210
Am J Otolaryngol. 2013 Sep-Oct;34(5):477-89
pubmed: 23731850
N Engl J Med. 2020 Aug 6;383(6):e38
pubmed: 32502334
Eur Arch Otorhinolaryngol. 2020 Oct;277(10):2775-2781
pubmed: 32577902
Adv Food Nutr Res. 2002;44:247-346
pubmed: 11885138
J Allergy Clin Immunol. 2015 Dec;136(6):1460-1470
pubmed: 26409662
Laryngoscope. 2021 May;131(5):1095-1100
pubmed: 33404079
PLoS One. 2020 Dec 10;15(12):e0242958
pubmed: 33301459
Curr Allergy Asthma Rep. 2018 Jun 15;18(8):42
pubmed: 29904888
Nat Med. 2020 Jul;26(7):1037-1040
pubmed: 32393804
Rhinology. 2020 Dec 1;58(6):623-625
pubmed: 32812014
Nat Med. 2020 Jul;26(7):1017-1032
pubmed: 32651579
Front Med. 2020 Apr;14(2):185-192
pubmed: 32170560
Lancet. 2020 Feb 22;395(10224):542-545
pubmed: 32061313
Int J Med Sci. 2019 Jan 1;16(2):253-263
pubmed: 30745806

Auteurs

Alexander Kusnik (A)

Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Clincial Cooperation Unit Healthy Metabolism, Center for Preventive Medicine Baden-Württemberg, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Christel Weiss (C)

Department of Statistics, Biomathematics and Information Processing, Heinrich Lanz Center for Digital Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Melanie Neubauer (M)

Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Bianca Huber (B)

Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Marlis Gerigk (M)

Institute of Medical Microbiology and Hygiene, Medical Faculty of Mannheim, University of Heidelberg, Mannheim, Germany.

Thomas Miethke (T)

Institute of Medical Microbiology and Hygiene, Medical Faculty of Mannheim, University of Heidelberg, Mannheim, Germany.
Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty of Mannheim, Heidelberg University, Mannheim, Germany.

Nicole Hunter (N)

Institute of Medical Microbiology and Hygiene, Medical Faculty of Mannheim, University of Heidelberg, Mannheim, Germany.

Nicole Rotter (N)

Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Sonja Ludwig (S)

Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Angela Schell (A)

Department of Otorhinolaryngology, Head and Neck Surgery, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Matthias P Ebert (MP)

Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Clincial Cooperation Unit Healthy Metabolism, Center for Preventive Medicine Baden-Württemberg, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Andreas Teufel (A)

Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. andreas.teufel@medma.uni-heidelberg.de.
Clincial Cooperation Unit Healthy Metabolism, Center for Preventive Medicine Baden-Württemberg, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. andreas.teufel@medma.uni-heidelberg.de.
Department of Medicine II, Division of Hepatology, Division of Clinical Bioinformatics, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. andreas.teufel@medma.uni-heidelberg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH